XWELL, Inc. (XWEL)
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Last price
- $0.73
- As of
Kresmion compiles this page from XWEL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
XWELL, Inc. (XWEL): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-08.
See the full XWEL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XWEL on one page. Preview it with sample data, then open it live with a free account.
Preview the XWEL dossierActive signals for XWEL
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +430% to XWEL (2026Q2)
- mediumEARNINGS_MISS
Q4-2022: Missed consensus by 83.8% - EPS $-3 vs $-1.632 estimate
- mediumEARNINGS_BEAT
Q1-2023: Beat consensus by 47.2% - EPS $-1.4 vs $-2.652 estimate
- mediumEARNINGS_MISS
Q3-2023: Missed consensus by 191.7% - EPS $-2.38 vs $-0.816 estimate
- mediumEARNINGS_MISS
Missed consensus by 83.8% - EPS $-3 vs $-1.632 estimate
FREE, NO ACCOUNT
Every signal on XWEL, as it fires
You are seeing 5 of 7 signals recorded on XWEL since 2026-05-17.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XWEL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 98420U802 · 2026Q2 | $122K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XWEL
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
XWEL against its peers
XWEL's operating margin of -53.6% ranks in the 47th percentile of 15 Diagnostics & Research sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | XWEL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 29.2M USD | 31.5M USD | 50 | 16 |
| Gross margin | 25.7% | 62.3% | 4 | 11 |
| Operating margin | -53.6% | -34.7% | 47 | 15 |
| Net margin | -58.2% | -34.5% | 38 | 16 |
| Return on equity | n/a | -15.4% | n/a | 14 |
| 1 year | -31.8% | -37.9% | 54 | 13 |
Peers (20): NDRA, ADVB, AWHL, LDDD, ISPC, IDXG, PRPO, MBAI, MDXH, FUNI, IMDX, NSTM, QUCY, FONR, BNR, BDSX, PRPH, OPK, PSNL, NEO. Left out: BIAF (no annual filing), PMDI (period gap), NOTV (no annual filing), ANPCF (no annual filing), AVCRF (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (XWEL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XWEL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XWEL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.